Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 15/20 | 1.00 |
| ▸ | CCNK | O75909 | 15/20 | 1.00 |
| ▸ | CDK9 | P50750 | 15/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 15/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 14/20 | 1.00 |
| ▸ | CDK2 | P24941 | 14/20 | 1.00 |
| ▸ | CDK7 | P50613 | 13/20 | 1.00 |
| ▸ | CCNH | P51946 | 12/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 1/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 11/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24839342 | 1.00 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL20190942 | 1.00 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29613489 | 1.00 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL17150537 | 0.94 | CCNK (0.89) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25328316 | 0.94 | CCNK (0.89) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29596542 | 0.94 | CCNK (0.89) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL30523927 | 0.94 | CCNK (0.89) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25329765 | 0.90 | CDK2 (0.83) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL17141346 | 0.89 | CDK2 (0.79) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24839797 | 0.88 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148210-A1 | CYCLIN-DEPENDENT KINASE 12 MODULATORS AND THERAPEUTIC USES THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | WO | disclosed |
| US-11932625-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2023143482-A1 | 2-AMINOPYRIMIDINE COMPOUND OR SALT, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-01-05 | — | — | US | disclosed |
| US-20220213067-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3544971-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2021087138-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | US | disclosed |
| EP-3544971-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098361-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CCNT1 39/4885CCNK 19/4885CDK9 22/4885 |
| US-11932625-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | CDK12, CDK1, CDK13 | CCNT1 39/4885CCNK 19/4885CDK9 22/4885 |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, RB1, MKI67 | CCNT1 41/4885CCNK 10/4885CDK9 5/4885 |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CCNT1 39/4885CCNK 19/4885CDK9 22/4885 |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | CDK12, CDK1, CDK13 | CCNT1 39/4885CCNK 19/4885CDK9 22/4885 |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CCNT1 39/4885CCNK 19/4885CDK9 22/4885 |
| US-20220213067-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CCNT1 39/4885CCNK 19/4885CDK9 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.